Wall Street brokerages expect Insulet Co. (NASDAQ:PODD) to announce sales of $162.28 million for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Insulet’s earnings. The lowest sales estimate is $161.25 million and the highest is $163.49 million. Insulet reported sales of $130.52 million in the same quarter last year, which would suggest a positive year over year growth rate of 24.3%. The business is scheduled to announce its next earnings results after the market closes on Monday, February 25th.

According to Zacks, analysts expect that Insulet will report full-year sales of $561.26 million for the current year, with estimates ranging from $560.17 million to $562.40 million. For the next year, analysts forecast that the business will report sales of $690.17 million, with estimates ranging from $665.93 million to $713.12 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Insulet.

A number of brokerages have recently issued reports on PODD. BidaskClub cut Insulet from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Oppenheimer set a $100.00 price objective on Insulet and gave the stock a “hold” rating in a research note on Friday, November 2nd. ValuEngine cut Insulet from a “strong-buy” rating to a “buy” rating in a research note on Monday, January 7th. Morgan Stanley upped their price objective on Insulet from $96.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 11th. Finally, UBS Group began coverage on Insulet in a research note on Tuesday, November 27th. They set a “buy” rating and a $105.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $99.87.

In related news, SVP David Colleran sold 6,113 shares of the stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $80.41, for a total value of $491,546.33. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Aiman Abdel-Malek sold 602 shares of the stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $80.41, for a total value of $48,406.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,541 shares of company stock worth $926,033. 3.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cutler Group LP acquired a new position in Insulet in the 4th quarter valued at $126,000. Parallel Advisors LLC grew its holdings in Insulet by 198.7% in the 4th quarter. Parallel Advisors LLC now owns 2,240 shares of the medical instruments supplier’s stock valued at $177,000 after buying an additional 1,490 shares in the last quarter. SNS Financial Group LLC acquired a new position in Insulet in the 3rd quarter valued at $225,000. CIBC Asset Management Inc acquired a new position in Insulet in the 3rd quarter valued at $227,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Insulet by 8.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,873 shares of the medical instruments supplier’s stock valued at $307,000 after buying an additional 305 shares in the last quarter.

Shares of Insulet stock opened at $81.72 on Wednesday. Insulet has a 12-month low of $70.80 and a 12-month high of $108.90. The company has a market cap of $4.88 billion, a PE ratio of -177.65 and a beta of 1.57. The company has a current ratio of 4.58, a quick ratio of 3.99 and a debt-to-equity ratio of 2.95.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

See Also: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.